Table 2.
Demographic and clinical characteristics of COVID SARS-COV-2 positive patients by age group and previous flu vaccination.
| Age <65 Years | Age 65+ Years | |||||
|---|---|---|---|---|---|---|
| Total Case (N.) | Vaccinated Cases (%) | p | Total Case (N.) | Vaccinated Cases (%) | p | |
| COVID-19 diagnosed cases | 57,465 | 7008 (12.2%) | 58,480 | 33,094 (56.6%) | ||
| Centre | ||||||
| Lombardy | 36,760 | 4428 (12.0%) | 0.003 | 42,728 | 23,604 (55.2%) | <0.001 |
| Veneto | 10,059 | 1180 (11.7%) | 7678 | 4835 (63.0%) | ||
| Tuscany | 4673 | 618 (13.2%) | 3618 | 1980 (54.7%) | ||
| Reggio Emilia | 2268 | 322 (14.2%) | 1937 | 1160 (59.9%) | ||
| Latium | 3705 | 460 (12.4%) | 2519 | 1515 (60.1%) | ||
| Gender | ||||||
| Females | 31,051 | 3845 (12.4%) | 0.14 | 31,773 | 18,683 (58.8%) | <0.001 |
| Males | 26,414 | 3163 (12.0%) | 26,707 | 14,411 (54.0%) | ||
| Age, year | ||||||
| 18–49 | 27,358 | 2566 (9.4%) | <0.001 | |||
| 50–64 | 30,107 | 4442 (14.8%) | ||||
| 65–74 | 16,522 | 7125 (43.1%) | <0.001 | |||
| 75–84 | 21,349 | 12,400 (58.1%) | ||||
| 85+ | 20,609 | 13,569 (65.8%) | ||||
| Charlson index | ||||||
| 0 | 52,225 | 5749 (11.0%) | <0.001 | 31,483 | 16,922 (53.7%) | <0.001 |
| 1–2 | 4786 | 1102 (23.0%) | 20,932 | 12,479 (59.6%) | ||
| ≥3 | 454 | 157 (34.6%) | 6065 | 3693 (60.9%) | ||
| N. of hospitalizations (last 2 years) | ||||||
| 0 | 48,463 | 5512 (11.4%) | <0.001 | 38,185 | 21,505 (56.3%) | 0.022 |
| 1 | 6375 | 946 (14.8%) | 10,671 | 6167 (57.8%) | ||
| ≥2 | 2627 | 550 (20.9%) | 9624 | 5422 (56.3%) | ||
| Comorbidities | ||||||
| Cerebrovascular diseases | 900 | 250 (27.8%) | <0.001 | 9814 | 6016 (61.3%) | <0.001 |
| Artery cardiac disease | 1529 | 377 (24.7%) | <0.001 | 14,271 | 8731 (61.2%) | <0.001 |
| Hypertension | 12,841 | 2173 (16.9%) | <0.001 | 38,248 | 21,664 (56.6%) | 0.73 |
| Hepatopathy | 475 | 110 (23.2%) | <0.001 | 1065 | 602 (56.5%) | 0.97 |
| Chronic kidney failure | 532 | 152 (28.6%) | <0.001 | 3436 | 1972 (57.4%) | 0.33 |
| Diabetes mellitus | 3045 | 699 (23.0%) | <0.001 | 12,078 | 7041 (58.3%) | <0.001 |
| Chronic pulmonary disease | 906 | 294 (32.5%) | <0.001 | 5908 | 3614 (61.2%) | <0.001 |
| Neoplasms | 2964 | 541 (18.3%) | <0.001 | 9081 | 5202 (57.3%) | 0.15 |
| Dementia | 88 | 44 (50.0%) | <0.001 | 5117 | 3287 (64.2%) | <0.001 |
| Rheumatic diseases | 416 | 93 (22.4%) | <0.001 | 1029 | 604 (58.7%) | 0.17 |
| Prior drug use a | ||||||
| Antiacid drugs | 9080 | 1551 (17.1%) | <0.001 | 23,474 | 13,385 (57.0%) | 0.086 |
| Lipid modifying agents | 4791 | 1003 (20.9%) | <0.001 | 16,963 | 9633 (56.8%) | 0.54 |
| Anticoagulants | 2962 | 484 (16.3%) | <0.001 | 11,402 | 6471 (56.8%) | 0.70 |
| Platelet aggregation inhibitors |
2306 | 593 (25.7%) | <0.001 | 15,112 | 8824 (58.4%) | <0.001 |
| Antiarrhythmics, class I and III |
434 | 87 (20.0%) | <0.001 | 2927 | 1682 (57.5%) | 0.33 |
| Antibiotics | 18,583 | 2485 (13.4%) | <0.001 | 21,226 | 11,927 (56.2%) | 0.14 |
| Anti HIV b drugs | 316 | 74 (23.4%) | <0.001 | 264 | 128 (48.5%) | 0.008 |
| Anti-Parkinsonian drugs | 116 | 40 (34.5%) | <0.001 | 1778 | 1099 (61.8%) | <0.001 |
| Antiepileptics | 2119 | 585 (27.6%) | <0.001 | 4857 | 2752 (56.7%) | 0.92 |
| Antipsychotics | 1175 | 401 (34.1%) | <0.001 | 4621 | 2718 (58.8%) | 0.001 |
| Antidepressants | 3794 | 667 (17.6%) | <0.001 | 9822 | 5840 (59.5%) | <0.001 |
| Corticosteroids for systemic use |
5347 | 845 (15.8%) | <0.001 | 7194 | 4024 (55.9%) | 0.23 |
| DMARDs c | 987 | 212 (21.5%) | <0.001 | 1183 | 602 (50.9%) | <0.001 |
| Recent drug use d | ||||||
| NSAIDs e | 2234 | 329 (14.7%) | <0.001 | 3582 | 2006 (56.0%) | 0.46 |
a within the last available 12 months prior Index Date; b HIV—Human Immunodeficiency Virus; c DMARDs—disease-modifying antirheumatic drugs; d within the last available 3 months prior Index Date; e NSAIDs—non-steroidal anti-inflammatory drugs.